Supplementary Materials for

NMI: a potential biomarker for tumor prognosis and immunotherapy

Teng He¹,†, Yinbiao Qiao²,†, Qi Yang³,†, Jie Chen¹, Yongyuan Chen⁴,⁵, Xiaoke Chen⁴,⁵, Zhixing Hao⁴,⁵, Mingjie Lin⁴,⁵, Zheyu Shao⁴,⁵, Pin Wu⁴,⁵,* and Feng Xu¹,*

¹Department of Infectious Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, China
²Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, China
³Department of Emergency, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, China
⁴Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, China
⁵Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310009, China

*Correspondence: Feng Xu, xufeng99@zju.edu.cn and Pin Wu, pinwu@zju.edu.cn
**Figure S1:**

Figure S1: The sensitivity of NMI to tumor diagnosis is represented by ROC curve (AUC > 0.7). (A) BLCA, (B) COAD, (C) ESCA, (D) HNSC, (E) KIRC, (F) KIRP, (G) LIHC, and (H) UCS.
**Figure S2:** The relationship between NMI and OS, DSS and PFI in tumor patients. (A) Adrenocortical carcinoma (ACC), (B) GBM, (C) COAD, (D) READ, (E) PAAD, (F) LIHC, and (G) osteosarcoma.
Figure S3: (A) Correlation between NMI and clinical features of LGG patients. ns, not significant.